10.3 Cerebral Palsy & Developmental Neurologic Management

Cerebral Palsy and Neurodevelopmental Management

Cerebral Palsy (CP) is the most common motor disability in childhood. It encompasses a heterogeneous group of permanent, but non-progressive, movement and posture disorders caused by a single or multiple non-progressive disturbances that occurred in the developing fetal or infant brain. While the primary insult is non-progressive, the clinical expression and secondary complications (such as severe musculoskeletal contractures) can change profoundly as the child grows. The CNRN must comprehend the varied classifications of CP and the intricate modalities utilized to manage severe hypertonia.

Etiology and Pathogenesis

The brain lesions that cause cerebral palsy can occur during the prenatal, perinatal, or postnatal periods (up to roughly 2-3 years of age).

• Prenatal factors account for the majority (70-80%) of cases and include genetic abnormalities, maternal infections (TORCH syndrome), placental insufficiency, and severe prematurity. Prematurity and low birth weight are the most significant risk factors, frequently leading to periventricular leukomalacia (PVL), a type of white matter brain injury strongly associated with spastic diplegia.
• Perinatal factors include birth asphyxia (hypoxic-ischemic encephalopathy, or HIE), which, contrary to historical belief, accounts for a minority of CP cases.
• Postnatal factors include severe traumatic brain injury, central nervous system infections (meningitis, encephalitis), and severe hyperbilirubinemia leading to kernicterus.

Classifications of Cerebral Palsy

CP is primarily classified by the predominant type of motor impairment and the topographical distribution of the affected limbs.

Motor Impairment Subtypes

1. Spastic Cerebral Palsy: This is by far the most common subtype, affecting approximately 75-80% of individuals with CP. It results from damage to the upper motor neurons in the pyramidal tract (motor cortex or corticospinal tract). Clinical features include marked hypertonia, exaggerated deep tendon reflexes, clonus, and a positive Babinski sign. Patients exhibit stiff, jerky movements and are at a high risk for developing debilitating joint contractures.
2. Dyskinetic Cerebral Palsy: Results from damage to the basal ganglia or extrapyramidal tracts. It is characterized by abnormal, involuntary, uncoordinated, and uncontrolled movements. These movements can be choreoathetoid (writhing, twisting) or dystonic (sustained muscle contractions leading to abnormal postures). The movements typically worsen with stress or excitement and disappear during sleep.
3. Ataxic Cerebral Palsy: Results from cerebellar damage. This is the least common type. It is characterized by poor balance, profound incoordination, a wide-based unsteady gait, and intention tremors. Fine motor skills are significantly impaired.
4. Mixed Cerebral Palsy: Many patients present with a combination of symptoms, most frequently a mix of spasticity and dyskinesia.

Management of Spasticity

Managing spasticity is a cornerstone of CP care, aiming to improve function, alleviate pain, facilitate hygiene, and prevent severe contractures. Management requires a tiered approach, starting with conservative measures and escalating to complex pharmacological and surgical interventions.

Pharmacological Interventions

• Oral Medications: Systemic medications like oral baclofen, diazepam, or tizanidine can reduce spasticity but frequently cause systemic side effects, notably unacceptable levels of sedation, which can impair cognition and function.
• Botulinum Toxin Injections (Botox): Targeted injections into specific spastic muscles block the release of acetylcholine at the neuromuscular junction, providing localized, temporary relief of spasticity (typically lasting 3-6 months). This allows a window of opportunity for intense physical therapy and casting.

Advanced Surgical Management

When oral medications and focal injections are insufficient, more aggressive neurosurgical interventions are considered.

Baclofen Pump Management: Intrathecal baclofen (ITB) therapy involves the surgical implantation of a programmable pump into the abdominal wall, connected to a catheter placed in the intrathecal space of the spinal canal. This delivers micro-doses of baclofen directly to the GABA receptors in the spinal cord, achieving profound spasticity reduction with minimal systemic sedation.

Nursing Considerations for ITB: The nurse must be acutely aware of the signs of pump malfunction, overdose, and withdrawal. Baclofen withdrawal is a medical emergency that can present with severe rebound spasticity, pruritus, hyperthermia, rhabdomyolysis, and multi-organ failure. It requires immediate medical intervention, often requiring high-dose oral or intravenous baclofen or benzodiazepines while the pump issue is resolved.

Selective Dorsal Rhizotomy (SDR): SDR is an irreversible neurosurgical procedure aimed at permanently reducing spasticity. The surgeon exposes the nerve roots in the lower spinal cord (typically L1 to S1). The sensory (dorsal) nerve rootlets are separated, and those transmitting abnormal, hyperactive reflex signals are identified using electromyography (EMG) and permanently severed. SDR is primarily indicated for patients with spastic diplegia who have good underlying muscle strength and trunk control. Postoperative care is intensive, requiring months of rigorous physical therapy to rebuild strength and relearn motor patterns.

Developmental Milestones and Screening

The early identification of CP relies heavily on vigilant pediatric assessment and the tracking of developmental milestones. Delays in gross motor milestones (e.g., failing to sit independently by 8 months or walk by 18 months) are major red flags. Other early indicators include abnormal muscle tone (either hypotonia or hypertonia in infancy), persistence of primitive reflexes (like the Moro or asymmetric tonic neck reflex beyond 6 months), and early development of clear hand preference (before 12 months), which strongly suggests hemiplegia on the contralateral side. The neuroscience nurse must advocate for early intervention programs, which leverage neuroplasticity to maximize developmental potential during the critical early years of life.